Last reviewed · How we verify
Risperidone and Ramelteon
This combination uses risperidone (a dopamine antagonist) to manage psychotic symptoms and ramelteon (a melatonin receptor agonist) to improve sleep disturbances.
This combination uses risperidone (a dopamine antagonist) to manage psychotic symptoms and ramelteon (a melatonin receptor agonist) to improve sleep disturbances. Used for Schizophrenia with comorbid insomnia, Bipolar disorder with sleep disturbance.
At a glance
| Generic name | Risperidone and Ramelteon |
|---|---|
| Sponsor | All India Institute of Medical Sciences, Bhubaneswar |
| Drug class | Atypical antipsychotic + melatonin receptor agonist combination |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Sleep Medicine |
| Phase | FDA-approved |
Mechanism of action
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms and agitation in schizophrenia and bipolar disorder. Ramelteon selectively agonizes melatonin MT1 and MT2 receptors to regulate circadian rhythm and promote sleep, addressing the common comorbid insomnia in psychiatric patients.
Approved indications
- Schizophrenia with comorbid insomnia
- Bipolar disorder with sleep disturbance
Common side effects
- Extrapyramidal symptoms (tremor, rigidity)
- Sedation
- Weight gain
- Prolactin elevation
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: